MedTrace Logo

Continuous Glucose Monitoring in Polycystic Ovarian Syndrome

NCT07392476 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-02-06

No results posted yet for this study

Summary

The purpose of this study is to learn more about blood sugar control in polycystic ovarian syndrome.

The patient will be asked to wear a continuous glucose monitor (CGM) device that is applied to the arm with a sensor or filament that goes under the skin to measure your sugar levels. The patient will wear this at certain time points throughout the study. There will have a total of 2 blood draws (about 1 tsp. of blood) at screening and the 6-month visit, a measure of the patients body muscle and fat (body composition), and fill out a questionnaire at the end of the first 3 months and 6 months.

Study participation in the research will last about 6 months.

Conditions

  • Polycystic Ovarian Syndrome (PCOS)

Interventions

DEVICE

Stelo glucose biosensor by Dexcom

Unblinded continuous glucose monitoring (CGM) system

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-24
Primary Completion
2026-12-31
Completion
2027-08-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07392476 on ClinicalTrials.gov